After the Ablation: StimCardio, Wearable Neuromodulation and the Next AF Outcome Gap
Dr. Dereck Mush, MD, MBA
StimCardio Medical
Investigational wrist-worn neuromodulation designed to complement catheter ablation for atrial fibrillation.
What they do
StimCardio Medical is a clinical-stage medical device company developing non-invasive wearable therapeutics for cardiac rhythm disorders. Its investigational Rhyvive device combines physiological sensing with closed-loop median nerve stimulation, with the goal of supporting patients after atrial fibrillation catheter ablation. CEO Amir Soltanianzadeh leads the company. A $30 million Series A announced October 29, 2026, led by Metis MedTech, is expected to fund the planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission. The device is investigational and has not received FDA clearance or approval. Cumulative funding was not disclosed in the announcement. John Slump, CEO and founder of Metis MedTech, and Joshua Phillips, managing partner of Catalyst Health Ventures, are identified as StimCardio board members in the release.
The record
- Vertical
- Cardiovascular
- Sub-segment
- Wearable neuromodulation
- Product type
- Device
- Stage
- Series A
- Headquarters
- Los Angeles, California, United States
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Notable investors: Metis MedTech, Catalyst Health Ventures.
Also in Cardiovascular
Related on The Signal
Dr. Dereck Mush, MD, MBA
Wearable cardiac monitoring is catching arrhythmias in men who would never have scheduled the test that found them
Dr. Dereck Mush, MD, MBA
Consumer sleep tracking has never been more precise. Diagnosing sleep disorders still requires a lab
Dr. Dereck Mush, MD, MBA
Next-Gen Neurotechnologies: Graphene Electrodes and Magnetic Surgical Robotics in Deep Brain Neuromodulation
Dr. Dereck Mush, MD, MBA